Table 1: List of studies included in the meta-analysis with details.
Author, year |
Country |
Type of Study |
Age in years (Dex, MTP) |
Total patients (Dex , MTP) |
Mortality (Dex , MTP) |
Need for mechanical ventilation (Dex , MTP) |
Additional treatment |
Ko, et al. (2021) [17] |
United States |
Retrospective cohort study |
57.8 ± 14.9, 56.2 ± 14.1 |
83, 104 |
26.5%, 16.4% |
43.5%, 45.7% |
Remdesevir, plasma therapy, hydroxychloroquine, tocilizumab (tocilizumab only in methylprednisolone cohort) |
Ranjbar, et al. (2021) [20] |
Iran |
Prospective triple blinded RCT |
61.3 ± 17.3, 56.2 ± 17.5 |
42, 44 |
37.5%, 18.6% |
38.1%, 18.2% |
None |
Pinzón, et al. (2021) [16] |
Colombia |
Ambispective cohort study |
63 (58-69), 64 (60-68) |
111, 105 |
17.1%, 9.5% |
19.8%, 2.9% |
Antibiotics, colchicine |
Fatima, et al. (2020) [18] |
Pakistan |
Quasi experimental, interventional study |
57.91 ± 16.4, 54.86 ± 14.3 |
35, 65 |
17.1%, 15.3% |
20%, 12.3% |
Tocilizumab, antibiotics, plasma therapy |
Plessis, et al. (2021) [19] |
South Africa |
Retrospective observational study |
54.5 (46-62), 52.0 (47.5-59) |
108, 46 |
66.7%, 60.9% |
63.9%, 50% |
None |
MTP: Methylprednisolone; Dex: Dexamethasone